Yuanyi (Shandong) Gene Technology Competitors and Similar CompaniesClear all

Impel Pharmaceuticals's competitors and similar companies include Tonix Pharmaceuticals, Precision Medicine Group and Brinton Pharmaceuticals.

	Impel Pharmaceuticals Impel Pharmaceuticals (formerly known as Impel NeuroPharma) is a pharmaceutical company that develops and commercializes therapies for patients suffering from central nervous system diseases.	Tonix Pharmaceuticals Tonix Pharmaceuticals develops pharmaceutical products for central nervous system disorders.	Precision Medicine Group Precision Medicine Group (PMG) is a company that specializes in advising clients on clinical trials, drug discovery, and commercialization.	Brinton Pharmaceuticals Brinton Pharmaceuticals is a pharmaceutical company operating in therapeutic and manufacturing areas.
Founding Date	Founding Date 2008	Founding Date 2007	Founding Date 2012	Founding Date 2014
Type	Type Public	Type Public	Type Subsidiary	Type Private
Tags	Tags Healthcare drug development medtech pharma	Tags Healthcare drug development medtech pharma	Tags Business Products & Services advertising brand creation clinical research market research public relations	Tags Healthcare drug development medtech pharma
Locations	Locations Seattle, US HQ	Locations Chatham, US HQ Montréal, CA Dublin, IE Dartmouth, US New York, US San Diego, US	Locations Bethesda, US HQ	Locations Pune, IN HQ Kumasi, GH London, GB Redding, US Sheridan, US
Employees	Employees 6710% increase	Employees 1633% increase	Employees 4044% increase	Employees 660
Valuation ($)	Valuation ($) 5.8 m	Valuation ($) 23.5 m	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $12.7m (FY, 2022)	Revenue (est.) $13.1m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) N/A
Cost of goods	Cost of goods $6.5m (FY, 2022)	Cost of goods $6.6m (FY, 2025)	Cost of goods N/A	Cost of goods N/A
Gross profit	Gross profit $6.2m (FY, 2022)	Gross profit $6.5m (FY, 2025)	Gross profit N/A	Gross profit N/A
Net income	Net income ($106.3m) (FY, 2022)	Net income ($124m) (FY, 2025)	Net income N/A	Net income N/A
Funding
Total funding raised	Total funding raised $ 108.1m	Total funding raised $ 15.5m	Total funding raised $ 359.7m	Total funding raised $ 12m